---
title: "J.P. Morgan Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)"
description: "Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, IDEAYA Biosciences, and AnaptysBio. According to TipRanks, Rama has an average return of 1.8% and a 46.75% success r"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261879181.md"
published_at: "2025-10-20T12:05:09.000Z"
---

# J.P. Morgan Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)

> Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, IDEAYA Biosciences, and AnaptysBio. According to TipRanks, Rama has an average return of 1.8% and a 46.75% success rate on recommended stocks. Currently, the analyst consensus on IDEAYA Biosciences is a Strong Buy with an average price target of $48.64, which is a 66.23% upside from current levels. In a report released yesterday, Citi also maintained a Buy rating on the stock with a $64.00 price target.

Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, IDEAYA Biosciences, and AnaptysBio. According to TipRanks, Rama has an average return of 1.8% and a 46.75% success rate on recommended stocks.

Currently, the analyst consensus on IDEAYA Biosciences is a Strong Buy with an average price target of $48.64, which is a 66.23% upside from current levels. In a report released yesterday, Citi also maintained a Buy rating on the stock with a $64.00 price target.

### Related Stocks

- [IDYA.US - Ideaya Biosciences](https://longbridge.com/en/quote/IDYA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| SG Americas Securities LLC 提升了其在 IDEAYA Biosciences, Inc. $IDYA 的持股 | SG Americas Securities LLC 在第三季度將其在 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) 的持股增加了 169.1%，目前持有 54,137 股，價值 147 萬美元。其他機構投資 | [Link](https://longbridge.com/en/news/272895771.md) |
| Truist Financial 維持對 Ideaya Biosciences (IDYA) 的買入評級 | Truist Financial 的分析師 Gregory Renza 對 IDEAYA Biosciences (IDYA) 維持了買入評級，目標價為 60.00 美元。Renza 是一位五星級分析師，平均回報率為 23.1%，成功率為  | [Link](https://longbridge.com/en/news/271649330.md) |
| Evercore ISI 維持對 CVS Health（西維斯）的買入評級 | Evercore ISI 分析師 Elizabeth Anderson 對 CVS Health (CVS) 維持了買入評級，目標價為 100.00 美元。Anderson 專注於醫療保健行業，推薦的平均回報率為 -2.1%，成功率為 48 | [Link](https://longbridge.com/en/news/275622408.md) |
| 摩根大通重申對 Sartorius（0NIR）的買入評級 | 摩根大通分析師 Richard Vosser 重申了對 Sartorius (0NIR) 的買入評級，目標價為 295.00 歐元。Vosser 是一位 3 星分析師，成功率為 48.87%，專注於醫療保健領域。Sartorius 還獲得了 | [Link](https://longbridge.com/en/news/275586209.md) |
| Berenberg 銀行重申其對諾和諾德公司（0QIU）的買入評級 | Berenberg Bank 分析師 Kerry Holford 重申了對諾和諾德公司 (0QIU) 的買入評級，目標價為 360.00 丹麥克朗。Holford 是一位四星級分析師，成功率為 59.14%，專注於醫療保健領域。最近，德意志 | [Link](https://longbridge.com/en/news/275719942.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.